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Many microorganisms are able to produce a wide range of amphipathic compounds, with 
both hydrophilic and hydrophobic moieties present within the same molecule which allow 
them to exhibit surface activities at interfaces and are generally called biosurfactants or 
bioemulsifiers. These surface-active compounds (SAC) are mainly classified according to 
their mode of action, molecular weight and general physico-chemical properties.   
In literature, the terms ‘biosurfactants’ and ‘bioemulsifiers’ are often used interchangeably, 
however in general those that reduce surface and interfacial tension at gas-liquid-solid 
interfaces  are called biosurfactants and those that mainly reduce the interfacial tension 
between immiscible liquids or at the solid-liquid interfaces leading to the formation of more 
stable emulsions are called bioemulsifiers or bioemulsans.  The former group includes low-
molecular-weight compounds, such as lipopeptides, glycolipids, proteins, while the latter 
includes high-molecular-weight polymers of polysaccharides, lipopolysaccharides proteins 
or lipoproteins (Smyth et al., 2010a, 2010c).  
In heterogeneous systems, biosurfactants tend to aggregate at the phase boundaries or 
interfaces.  They form a molecular interfacial film that affects the properties (surface energy 
and wettability) of the original surface. This molecular layer, in addition to lowering the 
surface tension in liquids, also lowers the interfacial tension between different liquid phases 
on the interfacial boundary existing between immiscible phases and therefore can have an 
impact on the interfacial rheological behaviour and mass transfer.   
When at interfaces (solid- liquid, liquid-liquid or vapour-liquid), the hydrophobic moiety of 
the surface active molecules aggregates at the surface facing the hydrophobic phase (usually 
the oil phase) while the hydrophilic moiety is oriented towards the solution or hydrophilic 
phase (mainly water). Their diverse functional properties namely, emulsification, wetting, 
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foaming, cleansing, phase separation, surface activity and reduction in viscosity of heavy 
liquids such as crude oil, make them suitable for utilization for many industrial and 
domestic application purposes (Gautam & Tiagi, 2006; Franzetti et al., 2010a; Perfumo et al., 
2010a; Satpute et al., 2010b).  
During the past two decades biosurfactants have been under continuous investigation as a 
potential replacement for synthetic surfactants and are expected to have several industrial and 
environmental applications mainly related to detergency, emulsification, dispersion and 
solubilisation of hydrophobic compounds (Banat et al., 2000).  In addition, biosurfactants 
present several advantages over surfactants of a chemical origin, particularly in relation to 
their biodegradability, environmental compatibility, low toxicity, high selectivity and specific 
activity at extreme temperatures, pH and salinity (Banat 1995a, 1995b). Due to all these 
properties, they have steadily gained increased significance in industrial and environmental 
applications such as bioremediation, soil washing, enhanced oil recovery and other general oil 
processing and related industries (Perfumo et al., 2010b). Furthermore, potential commercial 
applications in several other industries including paint, cosmetics, textile, detergent, 
agrochemical, food and pharmaceutical industries begin to emerge (Banat et al., 2000).  
Numerous investigations in the field of biosurfactants/bioemulsifiers are leading to the 
discovery and description of many interesting chemical and biological properties and 
potential biomedical therapeutic and prophylactic applications.  In this chapter we will 
focus on the most recent and appealing biomedical and therapeutic applications of 
biosurfactants and bioemulsifiers with special emphasis on the most recent results in the 
fields of biotechnology, nanotechnology and bioengineering. 
2. Classification, properties and functional mechanisms of microbial surface-
active compounds 
Microbial surface-active compounds are a range of structurally diverse molecules produced 
by different microorganisms and are mostly therefore classified by their structural features, 
the producing organism and their molecular mass. Their hydrophilic moiety is mainly 
comprised of an acid, peptide cations, or anions, mono-, di- or polysaccharides while their 
hydrophobic moiety can be an unsaturated or saturated hydrocarbon chains or fatty acids. 
The structural orientation on the surfaces and inter phases confers the range of properties, 
such as the ability to lower surface and interfacial tension of liquids and the formation of 
micelles and microemulsions between these different phases (Chen et al., 2010a, 2010b).  
2.1 Low molecular weight compounds 
2.1.1 Lipopeptides 
Microbial surface-active compounds can be roughly divided into low molecular weight 
molecules that efficiently reduce surface and interfacial tension (biosurfactants) (Fig. 1.), and 
high molecular weight polymers that stabilize emulsions but do not lower the surface 
tension as much (bioemulsans or bioemulsifiers) (Fig. 2.) (Neu, 1996; Rosenberg, 2006; 
Rosenberg & Ron, 1997; Smyth et al., 2010a, 2010c).  
The most studied low-molecular-weight biosurfactant compounds are lipopeptides and 
glycolipids. Lipopeptides are mainly produced by members of the Bacillus species; they are 
composed of different families and each family is constituted of several variants, which can 
differ in their fatty acid chain and their peptide moiety (Dastgheib et al., 2008; Jacques, 2010; 
Thavasi et al., 2008, 2011).  
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Fig. 1. Chemical structures of the main low molecular weight microbial surface active 
compounds reported; surfactin, iturin A, mono & di-rhamnolipids, mannosylerythritol 
lipids, dimycolates trehalose lipids, acidic and lactonic sophorolipids. 
Surfactin, a cyclic lipopeptide produced by Bacillus subtilis is considered the most active 
biosurfactant discovered so far (Ron & Rosenberg, 2001).  Surfactin was discovered by 
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Arima et al., (1968) from the culture broth of Bacillus subtilis and it was named thus due to 
its exceptional surfactant activity (Peypoux et al., 1999). Natural surfactins are a mixture 
of isoforms A, B, C and D which are classified according to the differences in their amino 
acid sequences and possess various physiological properties (Shaligram & Singhal, 2010). 
Surfactin is composed of a seven amino-acid ring structure coupled to a fatty-acid chain 
via a lactone linkage. Surfactin-A has L-leucine, surfactin-B has L-valine and surfactin-C 
has L-isoleucine at the amino acid position involved in the lactone ring formation with the 
C14–C15 ǃ-hydroxy fatty acid. The amino-acid residues may vary and the presence of 
these variants can be related to alterations in the culture conditions such as providing 
substrate containing some specific amino-acid residues in the culture media (Jacques, 
2010).  
Another surfactin related compound is lichenysin, a lipopeptide discovered in the 
supernatant of Bacillus licheniformis culture (Horowitz et al., 1990). Its chemical structure and 
physio-chemical properties are similar to surfactin (McInerney et al., 1990). In particular, 
lichenysin has Glutamine amino-acid in position 1 while surfactin has Glutamic acid. Other 
surfactin-like compounds are pumilacidin A, B, C, D, E, F and G, a complex of acylpeptide 
antibiotics isolated from Bacillus pumilus culture supernatants  with interesting antiviral 
properties (Morikawa et al., 1992; Naruse et al., 1990). Among the lipopeptides belonging to 
the iturin family, iturin A is the most studied compound. It is a heptapeptide interlinked 
with a ǃ-amino-acid fatty acid with carbon chain length from C14 to C17 (Peypoux, 1978, as 
cited in Jacques, 2010) produced by Bacillus subtilis strains reported to have antifungal 
activities (Besson et al., 1976).  
Other members of the iturin family are iturin C, bacillomycin D, F, and Lc and mycosubtilin 
(Bonmatin et al., 2003). The family of fengycins includes fengycins A and B, 
lipodecapeptides which differ by their amino-acid residue in position 6 that can be Alanine 
or Valine and are known for their interesting fungitoxic and immunomodulating activities 
(Jacques, 2010). Other interesting lipopeptides are serrawettins, nonionic cyclodepsipeptide 
biosurfactants produced by Serratia marcescens (Matsuyama et al., 2010) and implicated with 
anti-tumor and anti-nematode activities. 
2.1.2 Glycolipids 
Are commonly mono or disaccharides compounds acylated with long chain fatty acids or 
hydroxyl fatty acids. Among them, rhamnolipids, mannosylerythritol lipids (MELs), 
sophorolipids and trehalolipids are the best-studied structural subclasses.  
Rhamnolipids are glycosides, produced mainly by Pseudomonas aeruginosa and by the 
Burkholderia genus, that are composed of one (for mono-rhamnolipids) or two (for di-
rhamnolipids) rhamnose sugar moieties linked to one or two ǃ-hydroxyfatty acid chains 
(Perfumo et al., 2006; Raza, 2009). These molecules display high surface activities and many 
potential applications in the biomedical field due to their antibacterial, antifungal, antiviral, 
antiadhesive reported properties (Abalos et al., 2001; Cosson et al., 2002; Kim et al., 2000; 
Remichkova et al., 2008; Sotirova et al., 2008; Yoo et al., 2005). They have also been used in 
the preparation of nanoparticles (Palanisamy & Raichur, 2009; Xie et al., 2006) and 
microemulsions (Nguyen & Sabatini, 2009; Xie et al., 2007).  
The mannosylerythritol (MELs) glycolipids are produced by the yeasts strains of the genus 
Pseudozyma sp. and Ustilago sp. from soybean oil or n-alkane (Arutchelvi & Doble, 2010). 
MELs are a mixture of partially acylated derivative of 4-O-β-D-mannopyranosyl-D-erythritol, 
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containing C2:0, C12:0, C14:0, C14:1, C16:0, C16:1, C18:0 and C18:1 fatty acids as the hydrophobic 
groups (Bhattacharjee et al., 1970, as cited in Arutchelvi & Doble, 2010). Based on the degree 
of acetylation at C4 and C6 position, and their order of appearance on the thin layer 
chromatography, the MELs are classified into MEL-A, -B, -C and –D (Arutchelvi & Doble, 
2010). MEL-A representing the diacetylated compound while MEL-B and MEL-C are 
monoacetylated at C6 and C4, respectively. The completely de-acetylated structure is known 
as MEL-D (Rau et al., 2005, as cited in Arutchelvi & Doble, 2010).  
MELs have recently gained attention due to their environmental compatibility, mild 
production conditions, structural diversity, self-assembling properties and versatile 
biochemical functions.  In particular, interesting applications have been described in the 
biomedical field as antimicrobial, antitumor and immunomodulating molecules, in the 
biotechnological field for gene and drug delivery, and in cosmetic applications as skin 
moisturizers (Arutchelvi & Doble, 2010).  
Sophorolipids are another extracellular glycolipids synthesized by some yeast species 
including Candida bombicola, Candida apicola, Rhodotorula bogoriensis, Wickerhaminella 
domercqiae and Candida batistae (Van Bogaert & Soetaert, 2010). They consist of two glucose 
units linked ǃ-1,2. The 6- and 6’-hydroxyl groups are generally acetylated. The lipid portion 
is connected to the reducing end through a glycosidic linkage. The terminal carboxyl group 
of the fatty acid can be in the lactonic form or hydrolyzed to generate an anionic surfactant 
(Rosenberg & Ron, 1999). Sophorolipids have been reported suitable for a number of 
application in the biomedical field including use as antimicrobial, antiviral and anticancer. 
They also have been used in the synthesis of metal-bound nanoparticles in cosmetic and 
pharmacodermatological products (Van Bogaert & Soetaert, 2010).  
Trehalose lipids are also a glycolipids containing threhalose as the sugar moiety which is a 
non-reducing disaccharide in which the two glucose units are linked in an ǂ,ǂ-1,1-glycosidic 
linkage. It is the basic component of the cell wall glycolipids in Mycobacteria and 
Corynebacteria (Franzetti et al., 2010b). The most reported trehalose lipid is trehalose 6,6’-
dimycolate, which is a ǂ-branched chain mycolic acid esterified to the C6 position of each 
glucose. Different trehalose containing glycolipids are known to be produced by several 
other microorganisms belonging to mycolates group, such as Arthrobacter, Nocardia, 
Rhodococcus and Gordonia. Rhodococcus genus in particular produced several types of 
trehalose lipids as reported by Lang & Philp (1998).  These glycolipids vary in the number 
and overall chain length (C20–C90) of the esterified fatty acids. Beside their known 
industrial applications, trehalose lipids recently attracted attention to their functions in cell 
membrane interaction and their potential as antitumor therapeutic agents (Aranda et al., 
2007, Harland et al., 2009, Imasato et al., 1990, Isoda et al., 1995, as cited in Shao, 2010; Ortiz 
et al., 2008, 2009; Zaragoza et al., 2009, 2010). 
2.2 High molecular weight biosurfactants 
These are generally grouped together as polymeric biosurfactants. They are produced by  
a number of different bacteria and are composed of lipoproteins, proteins, 
polysaccharides, lipopolysaccharides or complexes containing several of these structural 
types (Ron & Rosenberg, 2001; Rosenberg & Ron, 1997, 1999). The most commonly studied 
biopolymer is emulsan (Fig. 2.), a lipopolysaccharide isolated from Acinetobacter 
calcoacetius RAG-1 ATCC 31012 with a molecular weight of around 1,000 kDa (Rosenberg 
et al., 1979).  
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Fig. 2. Chemical structure of most known high molecular weight microbial surface active 
compound; emulsan. 
RAG-1 emulsan is a complex of an anionic heteropolysaccharide and protein (Rosenberg & 
Kaplan, 1987, as cited in Rosenberg & Ron, 1999). Its surface activity is due to the presence 
of fatty acids, comprising 15% of the emulsan dry weight, which are attached to the 
polysaccharide backbone via O-ester and N-acyl linkages (Belsky et al., 1979, as cited in 
Rosenberg & Ron, 1999).  
Another high molecular weight biosurfactant is alasan, a complex of an anionic polysaccharide 
and a protein with a molecular weight of around 1,000 kDa isolated from Acinetobacter 
radioresistens (Navon-Venezia et al., 1995, as cited in Smyth et al., 2010c). These high molecular 
weight biosurfactants generally possess effective emulsifying activity and are called 
bioemulsifiers. A large number of other polymeric compounds have been discovered but 
remain partially or totally uncharacterized (Smyth et al., 2010c).  Little is known in general 
about these bioemulsifiers other than the producing organism and the overall chemical 
composition of the crude mixture. Halomonas eurihalina produces an extracellular sulfated 
heteropolysaccharide (Calvo et al., 1998, as cited in Rosenberg & Ron, 1999). Pseudomonas 
tralucida produced an extracellular acetylated polysaccharide that was effective in emulsifying 
several insecticides (Appaiah & Karanth 1991, as cited in Rosenberg & Ron, 1999).  
Several bioemulsifiers are effective at high temperature, including the protein complex from 
Methanobacterium thermoautotrophium (De Acevedo et al., 1996, as cited in Rosenberg & Ron, 
1999) and the protein-polysaccharide-lipid complex of Bacillus stearothermophilus ATCC 
12980 (Gunjar et al., 1995, as cited in Rosenberg & Ron, 1999).  Yeasts produce a number of 
emulsifiers, which are particularly interesting because of the food-grade status of several 
yeasts which allows use in food related industries. Liposan is an extracellular emulsifier 
produced by Candida lipolytica (Cirigliano & Carman, 1985, as cited in Rosenberg & Ron, 
1999). It is composed of 83% carbohydrate and 17% protein. Mannanprotein emulsifiers are 
produced by Saccharomyces cerevisiae (Cameron et al., 1988, as cited in Rosenberg & Ron, 
1999). Many of these bioemulsifiers have been used in the food, cosmetic, and petroleum 
industries (Rosenberg & Ron, 1999).  
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2.3 Properties and functions of biosurfactants  
There is a growing interest in the study of the physicochemical and biological properties of 
biosurfactants because of their potential industrial applications (Cameotra & Makkar, 2004; 
Desai & Banat, 1997; Lang, 2002; Rodrigues et al., 2006a; Singh & Cameotra, 2004). The 
interesting biological activities displayed by these compounds constitute an added value to 
their potential uses (Lang et al., 1989; Lang & Wagner, 1993; Stanghellini & Miller, 1997, as 
cited in Sánchez et al., 2010). Due to these reasons, an intense research activity is currently 
directed toward identification of new biosurfactants and characterization of their chemical 
and biological properties (Biria et al., 2010; Morita et al., 2009a; Satpute et al., 2010a; Singh & 
Cameotra, 2004; Singh et al., 2007).  
The most obvious property of biosurfactants compounds is their ability to effectively lower 
water surface tension, and a number of approaches that measure directly the surface activity 
of biosurfactants can be used as screening methods for their detection. Among them, the 
most frequently used as quick and simple techniques are the drop collapse (Bodour and 
Miller-Maier, 1998) and the oil spreading tests (Morikawa et al., 2000) (Fig. 3).  
 
 
Fig. 3. Oil spreading test. This technique measures the diameter of clear zones caused when 
a drop of a biosurfactant-containing solution is placed on an oil–water surface (Morikawa et 
al., 2000). Photo courtesy by Fabrizio Rivardo. 
An efficient biosurfactant can reduce the surface tension between pure water and air from 
72mN/m to less than 30mN/m. Surfactin, as one of the most powerful biosurfactants, can 
reduce the surface tension of water from 72mN/m to 27mN/m (which is close to the 
minimum detectable value) at a concentration as low as 10 μM (Seydlová & Svobodová, 
2008). Rhamnolipids can similarly achieve such level of reduction (Hisatsuka et al., 1971, as 
cited in Muthusamy et al., 2008; Mohammad Abdel-Mawgoud et al., 2010). The 
sophorolipids from T. bombicola have been reported to reduce the surface tension to 
33mN/m (Muthusamy et al., 2008) while MELs and trehalose lipids to less than 30mN/m 
(Arutchelvi & Doble, 2010; Shao et al., 2010).  
As surfactant monomers are added into solution, the surface or interfacial tension will 
decrease until the biosurfactant reaches the critical micelle concentration (CMC). The CMC 
is defined as the minimum concentration necessary to initiate micelle formation (Becher, 
1965). Above the CMC no further reduction in surface or interfacial tension is observed. At 
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the CMC, surfactant monomers begin to spontaneously associate into structured aggregates 
such as micelles, vesicles or continuous bilayers. These aggregates are produced as a result 
of numerous weak chemicals interactions such as hydrophobic, van der Waals and 
hydrogen bonding (Maier, 2003; Raza et al., 2010). Since no chemical bonds are formed, 
these structures are fluid-like and are easily transformed from one state to another as 
conditions such as electrolyte concentration and temperature are changed (Lin, 1996).  
The aggregate structure depends on the polarity of the solvent in which the surfactant is 
dissolved. In an aqueous solution, the polar head groups of a micelle will be oriented 
outward toward the aqueous phase, and the hydrophobic tails will associate in the core of 
the micelle within an oil-in-water micelle. In contrast, in oil, the polar head groups will 
associate in the center of the micelle while the hydrophobic tails will be oriented toward the 
outside within the water–in-oil micelle (Soberón-Chávez & Maier, 2010). Efficient 
surfactants have a low CMC, i.e. less surfactant is necessary to decrease the surface tension 
(Seydlová & Svobodová, 2008).  
Biosurfactants are most effective and efficient at their CMC which can be 10–40 times lower 
than that of chemical surfactants, i.e. less surfactant is necessary to get a maximum decrease 
in surface tension (Desai & Banat, 1997). Another important property for industrial and 
biotechnological applications is that most biosurfactants surface activities are not affected by 
environmental conditions such as temperature and pH (Muthusamy et al., 2008) particularly 
those of glycolipids composition. It has been reported that lichenysin from B. licheniformis JF-
2 was not affected by temperature (up to 50 °C), pH (4.5–9.0) and NaCl and Ca 
concentrations up to 50 and 25 g/l respectively. A lipopeptide from B. subtilis LB5a was also 
stable after autoclaving (121°C/20 min) and after 6 months at –18°C; the surface activity did 
not change from pH 5 to 11 and NaCl concentrations up to 20% (Muthusamy et al., 2008).  
Moreover, unlike synthetic surfactants, microbial-produced compounds are easily degraded 
and are generally considered as low or non-toxic products and therefore, appropriate for 
pharmaceutical, cosmetic and food uses. Although little is known about the toxicity of 
microbial surfactants, some data in the literature suggest that they are less toxic than synthetic 
surfactants (Muthusamy et al., 2008). The synthetic anionic surfactant (Corexit) for example 
had an LC50 (lethal concentration to 50% of test species) against Photobacterium phosphoreum at 
approximately ten times lower concentrations than that for rhamnolipids, demonstrating the 
higher toxicity of the chemical-derived surfactant.  It was also reported that biosurfactants 
needed higher effective concentration to decrease 50% of test population values (EC50) and 
were degraded faster than commercial dispersants.  In another report, biosurfactants from P. 
aeruginosa were noted to have much less toxic and mutagenic activities when compared to 
synthetic surfactant Marlon A-350, which is widely used in the industry. 
Understanding the functional mechanisms of biosurfactants and bioemulsifiers is of great 
help to discover interesting applications. Surfactin, one of the most powerful biosurfactants, 
is known to destabilize membranes disturbing their integrity and permeability (Bernheimer 
et al., 1970). This is due to changes in physical membrane structure or through disrupting 
protein conformations which alter important membrane functions such as transport and 
energy generation (Ortiz et al., 2008, 2009; Sánchez et al., 2009, 2010; Sotirova et al., 2008; 
Van Hamme et al., 2006; Zaragoza et al., 2009).  
The molecular mechanisms of surfactin interactions with membrane structures have been 
described by Shaligram & Singhal (2010) and by Seydlová & Svobodová (2008). A key step 
for membrane destabilization and leakage is the dimerization of surfactin into the bilayer 
(Carrillo et al., 2003). The hypothetical mechanisms of surfactin interactions with 
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membranes exhibit a complex pattern of effects such as insertion into the lipid bilayers, 
chelating mono- and divalent cations, modification of membrane permeability by channel 
formation or membrane solubilization by a detergent-like mechanism. In vitro, the 
incorporation of surfactin into the membrane gives rise to dehydration of the phospholipid 
polar head groups and the perturbation of lipid packing which strongly compromise the 
bilayer stability, leading to the disturbance of the membrane barrier properties.  
These structural fluctuations may well explain the primary mode of the antibiotic action and 
the other important biological effects of this lipopeptide (Carrillo et al., 2003). The extent of 
perturbation of the phospholipid bilayer correlates with the concentration of surfactin. At 
low concentrations surfactin penetrates readily into the cell membrane, where it is 
completely miscible with the phospholipids and forms mixed micelles. At moderate 
concentrations, the lipopeptide forms domains segregated within the phospholipid bilayer 
that may contribute to the formation of ion-conducting pores in the membrane leading to 
membraine disruption and permeabilization at high concentrations, showing a stronger 
activity than that of Triton (Heerklotz et al., 2007, as cited in Seydlová & Svobodová, 2008).  
As biological amphiphilic molecules, biosurfactants naturally tend to self-assemble into 
hierarchically ordered structures using hydrogen bonding, hydrophobic and van der Waals 
interactions (Kitamoto et al., 2009). Glycolipids, and in particular MELs, are well known for 
their self-assembling properties, that are influenced by the stereochemistry of the saccharide 
head groups (Kitamoto et al., 2005). Some of glycolipid type surfactants, which possess 
relatively large hydrophilic head groups as compared to the hydrophobic parts, generally 
form micelles in a dilute aqueous solution. Other than spherical micelles, they also form 
oblate (disk-like) and prolate (rod-like) structures (Söderman, 2000, as cited in Kitamoto et 
al., 2009). As the surfactant concentration further increases, glycolipid/water systems start 
to form a range of liquid crystalline phases. In particular, glycolipid biosurfactants 
spontaneously self-assemble into a variety of molecular assemblies with well-defined 
and/or unique structures, such as sponge (L3), cubic (V2), hexagonal (H2), or lamellar (Lǂ) 
configurations (Imura et al., 2007, as cited in Kitamoto et al., 2009).  
Among these molecular assemblies, vesicles are one of the most intensively studied ones. 
MELs in particular, due to their efficient molecular orientation property and effective 
balance between hydrophilic and hydrophobic groups, are able to form giant vesicles of 
diameter larger than 10 µm (Kitamoto et al., 2002). In comparison, rhamnolipids show a pH-
sensitive conversion of molecular assemblies due to the presence of a carboxyl group on the 
side chain (Kitamoto et al., 2002). This leads rhamnolipids to form micelles at pH more than 
6.8, lipid particles at pH 6.6-6.2, lamella structures at pH 6.5-6.0, and finally vesicles in the 
size of 50-100 nm at pH 5.8-4.3. Glycolipid biosurfactant-based vesicles or bilayer 
membranes appear, thus, to be very promising for exploiting useful nanostructured 
materials and/or systems.  
Another function of microbial surface-active molecules with interesting biotechnological 
potential is the ability to form stable emulsions (Fig. 4.). High molecular-mass biosurfactants 
are in general better emulsifiers than low-molecular-mass biosurfactants and are thus called 
bioemulsifiers. Bioemulsifiers, can form and stabilize oil in water or water in oil emulsions, 
but are not necessarily efficient detergents that are able to demonstrate remarkable surface 
tension reduction (Dastgheib et al., 2008). Emulsions can be produced with prolonged 
lifespan of months and years. Liposan, for example, does not reduce surface tension, but has 
been used successfully to emulsify edible oils (Cirigliano & Carman, 1985). Emulsan is an 
effective emulsifier at low concentrations (0.01-0.001%) representing emulsan-to-
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hydrocarbon ratios of 1:100 to 1:1000, while exhibiting considerable substrate specificity 
(Ron & Rosemberg, 2001). Polymeric surfactants offer additional advantages because they 
coat droplets of oil, thereby forming stable emulsions. This property is especially useful for 
making oil/water emulsions for cosmetics and food industries (Muthusamy et al., 2008). 
 
 
Fig. 4. Example of emulsion produced by the bioemulsifier extracted from the bacterial 
strain 7bCT5, isolated from a Cambodian soil. This emulsion is stable since 2009. 
2.3.1 Natural roles  
Although biosurfactants are produced by a large number of microorganisms and are clearly 
significant in many aspects of growth, it is difficult to generalize on their roles in microbial 
physiology. Due to their very diverse chemical structures and surface properties, different 
groups of biosurfactants may have different natural roles in the growth of the producing 
microorganisms and probably provide advantages in a particular ecological niche. Ron & 
Rosenberg, (2001) and Van Hamme et al., (2006) recently reviewed the physiological roles of 
microbial surface-active compounds. Some biosurfactants are essential for the motility of the 
microorganisms (gliding and swarming). For example, serrawettin plays a fundamental role 
for surface locomotion and access to water repelling surfaces for Serratia marcescens whereas 
surfactin, together with flagellar biosynthesis, are crucial for swarming motility in B. subtilis 
(Arutchelvi et al., 2008; Van Hamme et al., 2006). Bioemulsifiers also play an important role 
in regulating the attachment-detachment of microorganisms to and from surfaces (Van 
Hamme et al., 2006).  
In addition, bioemulsifiers are involved in cell-to-cell interactions such as bacterial 
pathogenesis, quorum sensing and biofilm formation, maintenance and maturation. 
Rhamnolipids, for example, are essential to maintain the architecture of the biofilms and are 
considered as one of the virulence factors in Pseudomonas sp. (Arutchelvi et al., 2008; Ron & 
Rosenberg, 2001; Van Hamme et al., 2006). Rhamnolipids, mannosylerythritol lipid and 
surfactin show antimicrobial and antibiotic properties thus conferring a competitive 
advantage to the organism during colonization and cell–cell competition. In addition 
cellular differentiation, substrate accession and resistance to toxic compounds are all roles 
attributed to microbial surface-active compounds.  Their most widespread role however is 
believed to be the interaction between microbes and insoluble substrates such as 
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hydrocarbons. Some biosurfactants/bioemulsifiers enhance the growth of bacteria on 
hydrophobic water-insoluble substrates by increasing their bioavailability, presumably by 
increasing their surface area, desorbing them from surfaces and increasing their apparent 
solubility (Neu, 1996; Ron & Rosenberg, 2001; Van Hamme et al., 2006). 
3. Biomedical applications of microbial surface-active compounds 
The use and potential commercial applications of biosurfactants in the medical field have 
increased during the past decade. Their antibacterial, antifungal and antiviral activities 
make them relevant molecules for applications in combating many diseases and as 
therapeutic agents. Furthermore, biosurfactants are generally considered safer than 
synthetic pharmaceuticals, due to their biological origin. Their pertinence in these fields is 
related to their biological properties such as the ability to disrupt membranes leading to cell 
lysis and metabolite leakage through increased membrane permeability and hence 
antimicrobial activity. Moreover, similarly to organic-conditioning films, their ability to 
partition at the interfaces can affect the adhesion properties of cells/microorganisms. 
Biomedical applications of biosurfactants have been thoroughly described (Banat et al., 2010; 
Cameotra & Makkar, 2004; Rodrigues et al., 2006a; Rodrigues & Teixeira, 2010; Seydlová & 
Svobodová, 2008; Singh & Cameotra, 2004).  
3.1 Antimicrobial activity of biosurfactants  
The search for new antimicrobial drugs remains a major concern nowadays because of the 
newly emerged pathogenic microorganisms and traditional others which have become 
virtually unresponsive to existing antibiotics. In fact, no novel or effective chemical 
antibiotics have been discovered during the last few decades (Hancock & Chapelle, 1999). 
Microbial metabolites have been recognized as a major source of compounds endowed with 
ingenious structures and potent biological activities (Donadio et al., 2002). Among these, 
some biosurfactants have been reported to be suitable alternatives to synthetic medicines 
and antimicrobial agents and may therefore be used as effective and safe therapeutic agents 
(Banat et al., 2000; Cameotra & Makkar, 2004; Singh & Cameotra, 2004). 
3.1.1 Antibacterial activity 
Lipopeptides have the most potent antimicrobial activity and have been a subject of several 
studies on the discovery of new antibiotics. The antibiotic activity is due to the ability of 
molecules of lipopeptide biosurfactants to self-associate and form a pore-bearing channel or 
micellular aggregate inside a lipid membrane (Carrillo et al., 2003; Deleu et al., 2008). 
Surfactin, in particular, has been associated with several physical and biological actions, 
such as antimicrobial, antiviral, anti-mycoplasma and haemolytic activities. It can penetrate 
into the membrane through hydrophobic interactions, thus influencing the ordering of the 
hydrocarbon chains and thus varying the membrane thickness (Bonmatin et al., 2003). Such 
membrane disruptions are a nonspecific mode of action and are advantageous for action on 
different cell membranes of both Gram-positive and Gram-negative bacteria (Lu et al., 2007). 
It has been suggested that such action by surfactin type peptides on membrane integrity 
rather than other vital cellular processes may perhaps constitute the next generation of 
antibiotics (Rodrigues & Teixeira, 2010).  Similar bioactive fractions from the marine Bacillus 
circulans biosurfactant had antimicrobial action against various Gram-positive and Gram-
negative pathogenic and semi-pathogenic bacteria including Micrococcus flavus, Bacillus 
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pumilis, Mycobacterium smegmatis, Escherichia coli, Serratia marcescens, Proteus vulgaris, 
Citrobacter freundii, Proteus mirabilis, Alcaligenes faecalis, Acetobacter calcoaceticus, Bordetella 
bronchiseptica, Klebsiella aerogenes and Enterobacter cloacae (Das et al., 2008). The chemical 
identity of this bioactive biosurfactant fraction showed overlapping patterns with that of 
surfactin lipopeptides and lichenysin. Mild antimicrobial action was also observed against 
methicillin-resistant Staphylococcus aureus (MRSA) and other MDR pathogenic strains. The 
biosurfactant was also found to be nonhaemolytic in nature thus indicating possible use as a 
drug in antimicrobial chemotherapy.  
Very recently Huang et al., (2011) evaluated antimicrobial activity of surfactin and 
polylysine against Salmonella enteritidis in milk using a response surface methodology and 
showed S. enteritidis to be very sensitive to both molecules with minimum inhibitory 
concentrations of 6.25 and 31.25 μg/mL, respectively. The optimization of antimicrobial 
activity indicated that S. enteritidis could be reduced by 6 orders of magnitude at a 
temperature of 4.45°C, action time of 6.9 h, and concentration of 10.03 μg/mL 
(surfactin/polylysine weight ratio, 1:1). 
In addition to surfactin, Bacillus subtilis strains produce a broad spectrum of bioactive 
peptides with great potential for biomedical applications, such as fengycin (Vanittanakom et 
al., 1986) and the iturin compounds: iturins (Besson et al., 1978; Peypoux et al., 1978), 
mycosubtilins (Peypoux et al., 1986), and bacillomycins (Peypoux et al., 1984), all of which 
are amphiphilic surface and membrane-active compounds with potent antimicrobial 
activities. Huang et al., (2007) reported that a lipopeptide antimicrobial substance produced 
by B. subtilis fmbj strain, which is mainly composed of surfactin and fengycin, was able to 
inactivate endospores of B. cereus through damaging the surface structure of the spores as 
seen by Transmission Electron Microscopy.  
Lichenysin, pumilacidin and polymyxin B (Grangemard et al., 2001; Landman et al., 2008; 
Naruse et al., 1990; Yakimov et al., 1995) are other antimicrobial lipopeptides produced by 
Bacillus licheniformis, Bacillus pumilus and Bacillus polymyxa, respectively. Polymyxin B, in 
particular, due to its high affinity for the lipid moieties of lipopolysaccharide, has shown 
antibacterial activities against a wide variety of Gram-negative pathogens. Being a cationic 
agent, it binds to the anionic bacterial outer membrane, leading to a detergent effect that 
disrupts membrane integrity. Important nosocomial pathogens such as Escherichia coli, 
Klebsiella spp., Enterobacter spp., Pseudomonas aeruginosa, and Acinetobacter spp. are usually 
susceptible to polymyxins and considerable activity has been reported against Salmonella 
spp., Shigella spp., Pasteurella spp., and Haemophilus spp. (Landman et al., 2008).  
Another promising example of an antimicrobial lipopeptide that is under commercial 
development is daptomycin (Cubicin®). It has been approved for the treatment of skin 
infections by the FDA in 2003 (Giuliani et al., 2007, as cited in Seydlová & Svobodová, 2008). 
Daptomycin produced by Streptomyces roseosporus has been shown to be highly active 
against multiresistant bacteria such as MRSA (Tally & De Bruin, 2000, as cited in Seydlová & 
Svobodová, 2008). Another lipopeptide with antimicrobial activity and other interesting 
biological properties is viscosin, a cyclic lipopeptide from Pseudomonas (Saini et al., 2008).  
Glycolipids, both rhamnolipids (Abalos et al., 2001; Benincasa et al., 2004) and sophorolipids 
(Kim et al., 2002; Van Bogaert et al., 2007) also have shown interesting antimicrobial activities 
(Fig. 5). Benincasa et al., (2004) reported that a mixture of six rhamnolipides homologues 
performed very well against Bacillus subtilis with a MIC of 8 µg/mL. Mannosylerythritol lipids 
(MEL-A and MEL-B) produced by Candida antarctica strains have also been reported to exhibit 
antimicrobial action against Gram-positive bacteria (Kitamoto et al., 1993).  
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Fig. 5. Measuring antimicrobial activity for rhamnolipids, sophorolipids and SDS at various 
concentrations above and below the CMC for these surface active molecules against Bacillus 
subtilis, red circles showing clearing/inhibition zones.  
Very recently, Nitschke et al., (2010) reported rhamnolipids produced by P. aeruginosa LBI 
with antimicrobial activity against several bacteria and fungi, including Bacillus cereus, 
Staphylococcus aureus, Micrococcus luteus, Mucor miehei and Neurospora crassa. Another 
glycolipid, flocculosin, a cellobiose lipid produced by the yeast-like fungus Pseudozyma 
flocculosa, was particularly effective against Staphylococcus species, including MRSA. Its 
antibacterial activity was not influenced by the presence of common resistance mechanisms  
against methicillin and vancomycin and it was able to eliminate C. albicans cells in a very 
short period of time (Mimee et al., 2009). 
Trehalose lipids produced by Tsukamurella sp. strain DSM 44370 together with trisaccharide 
and tetrasaccharide lipids also showed some activity against Gram-positive bacteria, with 
the exception of the pathogenic strain Staphylococcus aureus, whereas Gram-negatives were 
either slightly or not inhibited at all (Vollbrecht et al., 1999, as cited in Franzetti et al., 2010b). 
Studies carried out to elucidate the molecular interactions between this biosurfactant and 
the lipidic component of the membrane showed that trehalose lipid increased the fluidity of 
phosphatidylethanolamine and phosphatidylserine membranes and formed domains in the 
fluid state and did not modify the macroscopic bilayer organization (Ortiz et al., 2008, 2009).  
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3.1.2 Antiviral activity  
Antiviral effects have also been reported for surfactin and its analogues (Naruse et al., 1990). 
More effective inactivation of enveloped viruses, such as retroviruses and herpes viruses, 
were noted compared to non-enveloped viruses, suggesting that inhibitory action links may 
be due to physico-chemical interactions with the virus envelope (Vollenbroich et al., 1997a). 
Antiviral activity of some lipopeptides therefore may take place as a result of the viral lipid 
envelope and capsid disintegration due to ion channels formation, with consequent loss of 
the viral proteins involved in virus adsorption and/or penetration (Jung et al., 2000; 
Seydlová & Svobodová, 2008). 
In vitro experiments showed that both surfactin and fengycin produced by B. subtilis fmbj 
were able to inactivate cell-free virus stocks of porcine parvovirus, pseudorabies virus, 
newcastle disease virus and bursal disease virus and could effectively inhibit infections and 
replication of these viruses (Huang et al., 2006).  
Sophorolipids are also claimed to have activity against human immunodeficiency  
virus (Shah et al., 2005) and trehalose lipids (namely trehalose dimycolate, TDM) conferred 
higher resistance to intranasal infection by influenza virus in mice though inducing 
proliferation of T-lymphocytes bearing gamma/delta T-cell receptors, associated with the 
maintenance of acquired resistance to the infection (Hoq et al., 1997, as cited in Franzetti et 
al., 2010b).   
Rhamnolipid alginate complex also showed significant antiviral activity against herpes 
simplex virus types 1 and 2. In particular, they significantly inhibited the herpesvirus 
cytopathic effect in the Madin-Darby bovine kidney cell line (Remichkova et al., 2008). The 
suppressive effect of the compounds on herpes simplex virus replication was dose-
dependent and occurred at concentrations lower than the critical micelle concentration. 
3.1.3 Anti mycoplasma activity 
Some investigations have shown interesting anti-mycoplasma effects for surfactins. 
Mycoplasma contamination in cell culture is a frequently occurring serious limitation to 
biomedical research, particularly when it affects the irreplaceable cell lines which ultimately 
ends up destroyed. Earlier studies showed that surfactin treatment of mammalian cells that 
had been contaminated with mycoplasmas permitted specific inactivation of mycoplasmas 
without significantly damaging effects on cell metabolism in the culture (Vollenbroich et al., 
1997b). In a more recent study, surfactin was used to eliminate mycoplasma from an 
extensively infected irreplaceable hybridoma cell line (Kumar et al., 2007). There were 
apparent indications of limited elimination, suggesting the possible use of surfactin in 
achieving total decontamination. However, it was observed that surfactin was toxic to the 
infected hybridoma cells plated at various cell densities and exposure times, therefore it was 
suggested that preliminary tests should be carried out to determine the cytotoxicity of 
surfactin before use in decontamination.  
Another study confirmed surfactin potential to eliminate mycoplasma cells independently 
of the target cell, which is a significant advantage over the mode of action of conventional 
antibiotics (Fassi et al., 2007). This study also reported that surfactin exhibited a synergistic 
effect in combination with enrofloxacin, and resulted in mycoplasma-killing activity of 
about two orders of magnitude greater than when the molecules were used separately.  
3.1.4 Antifungal activity 
The antifungal activities of biosurfactants have long been known, although their action 
against human pathogenic fungi has been rarely described (Abalos et al., 2001; Chung et al., 
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2000; Tanaka et al., 1997). The previously mentioned cellobiose lipid flocculosin isolated 
from Pseudozyma flocculosa, was shown to display in vitro antifungal activity against several 
pathogenic yeasts, associated with human mycoses, including Candida lusitaniae, 
Cryptococcus neoformans, Trichosporon asahii and Candida albicans (Mimee et al., 2005). This 
product positively inhibited all pathogenic strains tested under acidic conditions and 
showed synergistic activity with amphotericin B. Moreover, no significant cytotoxicity was 
detected when tested against human cell lines.  In nature, flocculosin is part of P. flocculosa 
biocontrol arsenal against other fungi. Recent reports however have suggested that 
flocculosin is also used by P. flocculosa as a nutrient source when experiencing food 
limitation and the molecule is rapidly deacylated under alkaline conditions losing its 
antimicrobial activity which may explain conflicting results concerning the antimicrobial 
activity of this class of glycolipids (Mimee et al., 2009).  
Other antifungal activity of biosurfactants against phytopathogenic fungi has also been 
described. It has been recently demonstrated that glycolipids, such as cellobiose lipids 
(Kulakovskaya et al., 2009, 2010) and rhamnolipids (Debode et al., 2007, Banat et al, 2010) 
and cyclic lipopeptides (Tran et al., 2007, 2008, as cited in Banat et al, 2010), including 
surfactin, iturin and fengycin (Kim et al., 2010; Arguelles-Arias et al., 2009, Chen et al., 2009, 
Grover et al., 2010, Mohammadipour et al., 2009, Snook et al., 2009) can all have varying 
degrees of antimicrobial activities.   
3.2 Antiadhesion activity of biosurfactants  
Microbial biofilms formation on medical and technical equipment is an important and 
mostly hazardous occurrence, especially as the bacteria within such biofilms usually become 
highly resistant to antibiotics and adverse environmental challenges.  Several approaches 
have been adopted in order to limit pathogen colonization. Strict hygienic practices by 
healthcare personnel such as hand washing and regular disinfection of equipment and 
environment become of grave importance. However, it should be noted that routine 
disinfection is becoming controversial as frequent application becomes less effective 
(Dettenkofer et al., 2004, 2007, Kramer et al., 2006, as cited in Falagas & Makris, 2009).   
3.2.1 Biofilms on medical devices 
Device-related infections are often identified as having a biofilm aetiology and biofilm 
formation can occasionally be facilitated by the host inflammatory response molecules 
which can make adhesion to the surface of the device easier (Hall-Stoodley et al., 2004). 
Almost all kind of surfaces are suitable to be colonized by biofilms (Donlan & Costerton, 
2002). Biomedical devices are not the exception, biofilms are often found on the surface of 
urinary catheters (Stickler, 2008), central venous catheters (Petrelli et al., 2006), heart valves 
(Litzler et al., 2007), voice prostheses (Buijssen et al., 2007), contact lenses (Imamura et al., 
2008), hip prostheses (Dempsey et al., 2007) and intrauterine devices (Chassot et al., 2008).  
Current biofilm preventive strategies are essentially aimed at coating medical surfaces with 
antimicrobial agents, a process not always successful (Basak et al., 2009; von Eiff et al., 2005). 
Bacteria in biofilms become highly resistant to antibiotics, and so they evade host defenses 
withstanding antimicrobial chemotherapy (Morikawa, 2006). Since nosocomial infections 
remain an important problem even for hospitals with strict infection control programmes, 
infection control measures remain highly sought after (Falagas & Makris, 2009). 
Development of successful technologies based on the biofilm formation and growth control 
is expected to be a major breakthrough in the clinical practice and preventive medicine.  
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To eliminate biofilm formation novel compounds capable of specifically targeting biofilm 
growth while causing no adverse toxicity to the environment of application are needed. 
Several reports have suggested that, in addition to their direct action against pathogens, 
biosurfactants are able to interfere with biofilm formation, modulating microbial interaction 
with interfaces (Federle & Bassler 2003; Merk et al., 2005; Neu, 1996; Rasmussen & Givskov, 
2006; Rodrigues et al., 2006b, 2006c; Rodrigues et al., 2007). 
Surfactin for example has shown to be an important part of a list of biofilm controlling 
agents. Surfactin is able to inhibit biofilm formation of Salmonella typhimurium, S. enterica, E. 
coli and Proteus mirabilis in polyvinyl chloride wells, as well as vinyl urethral catheters 
(Mireles et al., 2001). Many Salmonella species are important opportunistic pathogens of the 
urinary tract system. Recently, two lipopeptide biosurfactants, produced by B. subtilis V9T14 
and B. licheniformis V19T21, showed the ability to selectively inhibit biofilm formation by 
pathogenic strains on polystyrene (Rivardo et al., 2009).  In particular, S. aureus ATCC 29213 
and E. coli CFT073 biofilm formation were decreased by 97% and 90%, respectively. V9T14 
biosurfactant was active on the Gram-negative strain yet ineffective against the Gram-
positive while the opposite was observed for V19T21 biosurfactant. These effect were 
observed either by coating the polystyrene surface with these compounds or by adding the 
biosurfactant to the inoculum. The chemical characterization of V9T14 lipopeptide 
biosurfactant carried out by LC/ESI-MS/MS revealed that it was composed of 77% of 
surfactin and of 23% of fengycin (Pecci et al., 2010).  
The activity of AgNO3 combined with the lipopeptide biosurfactant V9T14 has also been 
studied against a preformed E. coli biofilm on the Calgary Biofilm device (Rivardo et al., 
2010). Results indicated that the activity of silver can be synergistically enhanced by the 
presence of V9T14, allowing a reduction in the quantity of silver used to achieve greater 
antimicrobial impact. The concentrations of silver in the silver–biosurfactant solutions were 
129 to 258 fold less than the concentrations needed when silver was used alone. In another 
study, the V9T14 biosurfactant in association with antibiotics led to a synergistic increase in 
the efficacy of antibiotics in E. coli CFT073 biofilm innhibition and, in some combinations, to 
total eradication of the uropathogenic strain biofilm (Rivardo et al., 2011).  
In another recent work, marine bacterial culture supernatants of Bacillus pumilus and B. indicus 
significantly inhibited the initial attachment process and biofilm formation and dispersal of 
mature biofilms of Vibrio spp. strains (Nithya & Pandian, 2010). The bacterial supernatants also 
reduced the surface hydrophobicity of Vibrio spp. which is one of the important requirements 
for biofilm development. Valle et al., (2006) observed that distinct serotypes of group II 
capsular polysaccharides, produced by the uropathogenic E. coli (UPEC strain CFT073) 
behaved like surface-active polymers that displayed anti-adhesion properties. The treatment of 
abiotic surfaces with group II capsular polysaccharides drastically reduced both initial 
adhesion and biofilm development of important nosocomial pathogens.  
More recently, the effect of different temperatures on the anti-adhesive activity of surfactin 
and rhamnolipid biosurfactants was tested on polystyrene surfaces, regarding the 
attachment of Staphylococcus aureus, Listeria monocytogenes, and Micrococcus luteus (Zeraik & 
Nitschke, 2010). Surfactin inhibited bacterial adhesion at all tested conditions, and its 
activity increased with the decrease in temperature, giving a 63–66% adhesion reduction in 
the bacterial strains at 4°C. Rhamnolipids promoted a slight decrease in the attachment of S. 
aureus but were not as effective. The ability of rhamnolipid biosurfactant to inhibit adhesion 
of microorganisms to silicone rubber was also investigated in a parallel-plate flow chamber 
(Rodrigues et al., 2006c). The results showed an effective reduction in the initial deposition 
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rates and in the number of bacterial cells adhering after 4h, for several microorganisms. 
Moreover, perfusing the flow chamber with biosurfactant containing solution followed by 
the passage of a liquid–air interface produced high detachment (96%) of adhered cells for 
several microorganisms. These capabilites have a lot of implications regarding biofilm 
formation and microbial contamination and establishments on such biomedical devices 
made of such compounds. 
Antibiofilm activity was also reported for a glycolipid biosurfactant isolated from another 
marine bacterium Brevibacterium casei MSA19 against pathogenic biofilms in vitro (Kiran et al., 
2010a). The purified glycolipid disrupted the biofilm formation under dynamic conditions and 
the biofilm-forming capacity of both mixed culture and individual human and fish pathogenic 
strains was significantly inhibited at 30 mg/mL glycolipid. Raya et al., (2010) analyzed the 
effects of rhamnolipids and shear on initial attachment of Pseudomonas aeruginosa PAO1 in 
glass flow chambers. The presence of rhamnolipids significantly reduced the initial attachment 
of PAO1, even at the low concentration of 13 mg/L. Prewashing the cells with a 100 mg/L 
rhamnolipid solution, however, did not affect the attachment significantly. The initial cell 
attachment increased with increasing shear at the very low shear range (up to 3.5–5.0 mN/m2), 
however the attachment could be minimized with further increase of the shear.  
The biosurfactant Lunasan produced by the yeast Candida sphaerica UCP0995 completely 
inhibited the adhesion of Streptococcus agalactiae, Streptococcus sanguis 12, Streptococcus mutans, 
Streptococcus mutans NS, Staphylococus epidermidis, Staphylococus aureus and Candida albicans on 
plastic tissue culture plates at a concentration of 10 mg/ml and ≈92% inhibition of adhesion 
occurred for Pseudomonas aeruginosa (Luna et al., 2011). Lunasan, tested at the same 
concentration, also showed antimicrobial activity against the strains Streptococcus oralis (68%), 
Candida albicans (57%), and Staphylococcus epidermidis (57.6%). The same research group also 
described antiadhesive and antimicrobial activities of Rufisan, a biosurfactant produced by the 
yeast Candida lipolytica UCP 0988 (Rufino et al., 2011).  Crude biosurfactant showed anti-
adhesive activity at ≥0.75 mg/L against most of the microorganisms tested (Staphylococus 
aureus, Streptococcus agalactiae, Streptococcus mutans NS) and the anti-adhesive property was 
proportional to the concentration of the biosurfactant while antimicrobial activities were also 
observed at higher biosurfactant concentrations.  
In conclusion, the anti-adhesive activity of biosurfactants against several pathogens 
indicates their potential utility as coating agents for medical insertional materials that may 
lead to a reduction in a large number of hospital infections without the need for use of 
synthetic drugs and chemicals.  
3.2.2 Biofilms on food processing surfaces 
In addition to the treatment of biomaterials used for medical devices, biosurfactants have 
also been used in the pre-treatment of material surfaces found in food-processing 
environments. Pathogenic bacteria implicated in food-borne illness outbreaks are able to 
form biofilms on food contact surfaces that are more resistant to sanitation than free-living 
cells (Kalmokoff et al., 2001; Kim et al., 2006; Stepanovic et al., 2004). The pre-conditioning of 
surfaces using microbial surface-active compounds may be an interesting strategy for 
preventing the adhesion of food-borne pathogens to solid surfaces. Meylheuc et al., (2006b) 
demonstrated that the preconditioning of stainless steel surfaces with an anionic 
biosurfactant produced by Pseudomonas fluorescens reduced the number of L. monocytogenes 
LO28-adhering cells and thus favoured the bactericidal activities of the disinfectants sodium 
hypochlorite (NaOCl) and peracetic acid/hydrogen peroxide (PAH).  
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Similarly, biosurfactants obtained from Lactobacillus helveticus and P. fluorescens were able to 
inhibit the adhesion of four Listeria strains to stainless steel (Meylheuc et al., 2006a). 
Whichever strain of L. monocytogenes used in combination with biosurfactants, the anti-
adhesive biological coating developed both reduced the total adhering flora and the viable 
and culturable adherent bacteria on stainless steel surfaces. More recently, another group 
investigated the effect of rhamnolipid and surfactin biosurfactants on the adhesion of the 
food pathogens E. sakazakii, L. monocytogenes and S. enteritidis to polypropylene and stainless 
steel surfaces (Nitschke et al., 2009). Preconditioning with surfactin, rather than 
rhamnolipid, caused a reduction in the number of adhering cells particularly of L. 
monocytogenes and to some extent E. sakazakii on stainless steel. Surfactin showed a 
significant decrease in the adhesion on polypropylene of all strains. The adsorption of 
surfactin on polystyrene also reduced the adhesion of S. enteritidis- and L. monocytogenes-
growing cells. In addition, surfactin was able to delay bacterial adhesion within short 
contact periods using non-growing cells or longer contact periods using growing cells.  
Other antimicrobial and antiadhesive properties of a biosurfactant produced by Lactobacillus 
paracasei ssp. paracasei A20 isolated from a Portuguese dairy plant were also described 
(Gudiña et al., 2010). The biosurfactant had antimicrobial activity against a broad range of 
microorganisms including the pathogenic C. albicans, E. coli, S. aureus, S. epidermidis and 
Streptococcus agalactiae while exhibiting a considerable antiadhesive activity against a wide 
range of microorganisms. 
The activity demonstrated by biosurfactants suggests that they could be considered as new 
tools in developing strategies to prevent or delay microbiological colonization of industrial 
plant surfaces used in foodstuffs preparation. 
3.3 Probiotics biosurfactants activity 
Probiotics are: “Live microorganisms which when administered in adequate amounts confer 
a health benefit on the host”. They have been reported to have positive effects on the 
maintenance of human health (Gupta & Garg 2009). Interest in probiotics has gained great 
significance due to the increasing antimicrobial resistance of bacteria worldwide. Evidence 
suggests that probiotic organisms may have a role in lowering the incidence or the duration 
of antibiotic-related diarrhea, contributing to the prevention or treatment of vaginal 
candidiasis, bacterial vaginosis and recurrent lower urinary tract infections. Furthermore, 
they encourage improved immunological defense responses and can decrease the activity of 
numerous toxic antimetabolites (Falagas et al., 2006a, 2006b, 2007). 
Probiotics mechanisms of action vary, however, some are known to produce various 
antimicrobial agents such as organic acids, hydrogen peroxide, carbon peroxide, diacetyl, 
low molecular weight antimicrobial substances and bacteriocins (Merk et al., 2005). In 
addition, probiotics have long been known also for the capacity to interfere with the 
adhesion and formation of biofilms of pathogens to epithelial cells of urogenital and 
intestinal tracts (Reid et al., 1998, 2001).  The mechanisms of this interference include the 
release of surface active molecules (Gudiña et al., 2010; Rodrigues et al., 2006d).  Hong et al., 
(2005) reported the production of antimicrobial lipopeptides by Bacillus probiotics products 
as the main mechanisms by which they inhibit the growth of pathogenic microorganisms in 
the gastrointestinal tract. Similarly, competition with other microorganisms for adherence to 
epithelial cells as well as biosurfactants production are well known mechanisms used by 
Lactobacillus probiotics to interfere with  vaginal pathogens (Barrons & Tassone, 2008; Cribby 
et al., 2008; Falagas et al., 2007).  
www.intechopen.com
Biosurfactants and Bioemulsifiers Biomedical and  
Related Applications – Present Status and Future Potentials 
 
343 
Several investigators have pointed to evidence that probiotic type microorganisms and their 
biosurfactants may antagonize the growth of nosocomial pathogens on inanimate surfaces 
(Rodrigues et al., 2004a, 2004b, 2006b, 2006c; Walencka et al., 2008). Falagas & Makris, (2009) 
reviewed studies involving in vitro experiments on the potential role of probiotics 
microorganisms and their products in the inhibition of bacterial or fungal colonisation of 
artificial surfaces, such as vinyl urethral catheters and silicon rubber voice prostheses 
(Busscher et al., 1997, 1998; Velraeds et al., 1996, 1997, 2000; Rodrigues et al., 2004a, 2004b, 
2006b, Van der Mei et al., 2000). The majority of the investigators examined the 
preconditioning of the materials surfaces with probiotic biosurfactants, while others added 
probiotic biosurfactant producing strains to examin adhesion or biofilm development.  It 
was generally demonstrated that both probiotics microorganisms alone (mainly 
Streptococcus thermophilus and Lactobacillus spp. strains) or their biosurfactants were able to 
antagonize growth and development of potentially pathogenic microorganisms including 
Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus spp., Enterococcus faecalis, 
Candida albicans, Candida tropicalis (Busscher et al., 1997; Van Hoogmoed et al., 2000).  
Rodrigues et al., (2004a) demonstrated that the biosurfactant obtained from the probiotic 
bacterium Lactococcus lactis 53 was able to inhibit the adhesion of bacterial pathogens to 
silicone rubber with an adsorbed biosurfactant layer. Adhesion of yeasts was also decreased 
in the presence of biosurfactant, but to a lesser extent. In another work, using an artificial 
throat model, the same authors showed that biosurfactants obtained from probiotic strains 
greatly reduced microbial numbers on voice prostheses and induced a decrease in the 
airflow resistance of voice prostheses after biofilm formation, which may prolong the 
lifetime of indwelling silicone rubber voice prostheses (Rodrigues et al., 2004b).  
In a more recent work, it was demonstrated that the preconditioning of silicon rubber with a 
biosurfactant produced by the strain Streptococcus thermophilus A reduced adhering bacterial 
pathogens by up to 97% and adhering Candida spp. by up to 70% (Rodrigues et al., 2006b). 
Velraeds et al., (1996) also reported on the inhibition of adhesion of pathogenic enteric bacteria 
by a biosurfactant produced by a Lactobacillus strain and later showed that the biosurfactant 
caused an important dose-related inhibition of the initial deposition rate of E. coli and other 
bacteria adherent on both hydrophobic and hydrophilic substrata (Velraeds et al., 1997). 
Another interesting application area that is gaining increased interest relates to probiotics 
use in preventing oral infections (Çaglar et al., 2005; Hatakka et al., 2007; Kõll et al., 2008; 
Meurman, 2005; Meurman & Stamatova, 2007). Van Hoogmoed et al., (2004) demonstrated 
that Streptococcus mitis biosurfactant inhibited adhesion of Streptococcus sobrinus HG 1025 
and Streptococcus mutans ATCC 25175 to bare enamel, while S. mitis biosurfactant was able 
to inhibit the adhesion of S. sobrinus HG 1025 to salivary pellicles. The authors later reported 
that these reductions may be attributed to increased electrostatic repulsion between the 
bacteria and the biosurfactant-coated pellicles (Van Hoogmoed et al., 2006). 
New biosurfactant molecules produced by probiotic bacteria are reported from dairy 
products and environment. Recent work by Walencka et al., (2008) demonstrated that 
surfactants obtained from three Lactobacillus acidophilus strains inhibited S. epidermidis and S. 
aureus biofilm integrity and formation.  Moreover, surfactant addition to preformed mature 
biofilms accelerated their dispersal and altered the characteristics of the biofilm 
morphology. A novel xylolipid biosurfactant from Lactococcus lactis, a probiotic strain 
isolated from a traditional Indian fermented dairy product, showed a good antibacterial 
activity against clinical pathogens of E. coli and MRSA strains (Saravanakumari & Mani, 
2010). Xylolipid was non-pathogenic and safe for oral consumption and dermal applications, 
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suggesting that it could be safely used as a therapeutic agent or as a preservative in food or 
cosmetic products. 
In another recent work, a biosurfactant producing strain, Lactobacillus sp. CV8LAC, isolated 
from fresh cabbage, showed interesting antiadhesive activity against two C. albicans 
pathogenic biofilm-producing strains (CA-2894 and DSMZ 11225) (Fracchia et al., 2010). The 
CV8LAC biosurfactant significantly inhibited the adhesion of fungal pathogens to 
polystyrene microtiter plates in pre-coating and co-incubation experiments. In pre-coating 
assays, biofilm formation of strain CA-2894 was reduced by 82% at concentration of  
312.5 µg/mL while that of strain DSMZ 11225 was reduced by 81% at 625 µg/mL.  
In co-incubation assays, biofilm formation of the two strains was inhibited by 70% at 160.5 
µg/well and by 81% at 19.95 µg/well, respectively. It was interesting to note that no 
inhibition of both C. albicans planktonic cells was observed, thus indicating that the 
biosurfactant displayed specific anti-biofilm formation but not antimicrobial activity. 
Considering their importance for human health and their recognized safety, environmental 
probiotic organisms may, thus, represent a safe and effective intervention for infection 
control purposes. Probiotics themselves or their products (biosurfactants), could be applied 
to patient care equipment, such as tubes or catheters, with the aim of decreasing the 
colonisation of these sites by nosocomial pathogens and potentially impede a central step in 
the pathogenesis of nosocomial infections (Falagas & Makris, 2009).   
3.4 Other promising biological activities 
Biosurfactants have been shown to have many other roles in biomedical application. Some 
of the most powerful molecules (eg. surfactin, mannosylerythritol lipids (MELs), trehalose 
lipids) are known to have anti-inflammatory, anti-tumour, immunosuppressive and 
immunomodulating functions, in addition to other properties such as self-assembling, 
human cells stimulation and differentiation, interaction with stratum corneum lipids, cell-to-
cell signaling, hemolytic activity. 
3.4.1 Anti-tumor activity 
Recently, it has been demonstrated that these interesting microbial products can control a 
variety of mammalian cell functions. They are considered to participate in various 
intercellular molecular recognitions such as signal transduction, cell differentiation, cell 
immune response, etc. (Osada, 1998). Cao et al., (2010) demonstrated that surfactin induces 
apoptosis in human breast cancer MCF-7 cells through a ROS/JNK-mediated 
mitochondrial/caspase pathway. In a more recent work, they investigated the reactive 
oxygen species (ROS) and Ca2+ impact on mitochondria permeability transition pore (MPTP) 
activity, and MCF-7 cell apoptosis induced by surfactin (Cao et al., 2011). The results 
showed that surfactin initially induced the ROS formation, leading to the MPTP opening 
accompanied with the collapse of mitochondrial membrane potential which lead to an 
increase in the cytoplasmic Ca2+ concentration. In addition, cytochrome c was released from 
mitochondria to cytoplasm through the MPTP which activated caspase-9, eventually 
inducing apoptosis.   
In another study, viscosin, an effective surface-active cyclic lipopeptide recovered from 
Pseudomonas libanensis M9-3, inhibited the migration of the metastatic prostate cancer cell 
line, PC-3M, without visible toxicity effects (Saini et al., 2008). More recently, lipopeptides 
(namely isoforms of surfactins and fengycins) derived from a marine Bacillus circulans DMS-
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2 showed interesting cytotoxic activity against cancer cell lines (Sivapathasekaran et al., 
2010). The purified lipopeptides at a concentration of 300 µg/mL showed more than 90% 
inhibition of proliferation on both colon cancer cell lines HCT 15 and HT 29 after 24 h 
treatment and the antiproliferative activity of lipopeptides was observed in a dose 
dependent manner.   
Significant effects against both tumor cell lines as compared to non-tumor cell line were also 
observed, thus indicating the selective inhibitory activity of these molecules. Serratamolide 
AT514, cyclic depsipeptide from Serratia marcescens, belonging to the group of serrawettins, 
has also been reported to be a potent inducer of apoptosis of several cell lines derived from 
various human tumors and B-chronic lymphocytic leukemia cells, primarily involving the 
mitochondria-mediated apoptotic pathway and interference with Akt/NF-kB survival 
signals (Escobar-Díaz et al., 2005, as cited in Matsuyama et al., 2010). Biological studies of 
AT514 using human B-lymphocytes are now in progress for clinical applications of AT514 in 
the field of medical oncology. 
Interesting anti-tumor activities has also been reported for glycolipids. Mannosylerythritol 
lipids (MELs) are among the most promising biosurfactants known due to their versatile 
interfacial and biochemical actions. Interesting studies, thoroughly reviewed by Kitamoto et 
al. (2002) and by Arutchelvi & Doble, (2010), have shown that MEL-A and MEL-B display 
excellent growth inhibition and differentiation-inducing activities against human leukemia 
cells including myelogenous leukemia cell K562, promyelocytic leukemia cell HL60, and the 
human basophilic leukemia cell line KU812, as well as growth inhibition activity of mouse 
melanoma B 16 cells. Recently Chen et al., (2006) also demonstrated that a sophorolipid 
produced from the yeast Wickerhamiella domercqiae induced apoptosis in H7402 human liver 
cancer cells by blocking cell cycle at G1 phase and partly at S phase, activating caspase-3, 
and increasing Ca2+ concentration in cytoplasm. 
3.4.2 Anti-inflamatory activity 
Byeon et al., (2008) observed that surfactin was able to downregulate LPS-induced nitric oxide 
production in RAW264.7 cells and primary macrophages by inhibiting NF-κB activation, 
suggesting a good potential as a bacterium-derived anti-inflammatory agent. Selvam et al., 
(2009) studied the effect of B. subtilis PB6, a natural probiotic, on plasma cytokine levels in 
inflammatory bowel disease and colon mucosal inflammation. The strain was found to secrete 
surfactins which are known to inhibit phospholipase A2, involved in the pathophysiology of 
inflammatory bowel disease. In animal experiments carried out in rat models for 
trinitrobenzene sulfonic acid-induced colitis, oral administration of PB6 as a probiotic 
suppressed colitis as measured by mortality rate and changes in colon morphology and weight 
gain. Plasma levels of pro-inflammatory cytokines were also significantly lowered and the 
anti-inflammatory cytokine significantly increased after the oral administration of PB6, 
supporting the concept that PB6 inhibits PLA2 by secreting surfactins.  
In another work, surfactin isomers derived from the mangrove bacterium Bacillus sp. (No. 
061341) showed interesting anti-inflammatory activities (Tang et al., 2010).  In particular, 
this class of cyclic lipopeptide showed strong inhibitory properties on the overproduction of 
nitric oxide and the release of IL-6 in LPS-induced murine macrophage cell RAW264.7. 
Moreover, structure-activity relationship studies revealed that the existence of the free 
carboxyl group in the structure of surfactin isomer was crucial as to the anti-inflammatory 
activities. An interesting recent study explored the mechanisms responsible for surfactin-
induced anti-inflammatory actions in the context of periodontitis caused by Porphyromonas 
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gingivalis, the major pathogen of periodontal disease (Park et al., 2010). The Authors 
observed that surfactin significantly reduces pro-inflammatory cytokines, including tumor 
necrosis factor-ǂ, interleukin (IL)-1ǃ, IL-6, and IL-12, through suppression of nuclear factor-
κB activity in P. gingivalis LPS-stimulated THP-1 human macrophage cells, in a Heme 
oxygenase-1 (HO-1)-dependent fashion. Furthermore, surfactin treatment effectively 
induces HO-1 expression, a major defense in response to oxidative stress.  
These observations support the potential of surfactin as a candidate in strategies to prevent 
caries, periodontitis, or other inflammatory diseases. 
3.4.3 Immuno-modulatory action 
Park & Kim, (2009) studied the role of surfactin in the inhibition of the immunostimulatory 
function of macrophages through blocking the NK-κB, MAPK and Akt pathway. This 
provided a new insight into the immunopharmacological role of surfactin in autoimmune 
disease and transplantation. Their work indicated that surfactin has potent 
immunosuppressive capabilities which suggested important therapeutic implications for 
transplantation and autoimmune diseases, including allergy, arthritis and diabetes.  
A biosurfactant glycolipid complex from Rhodococcus ruber was also shown to activate the 
production of IL-1beta and TNF-alpha cytokines without modifying the production of IL-6, 
thus suggesting good prospects for further studies of immunomodulating and antitumor 
activities (Kuyukina et al., 2007). 
3.4.4 Other biomedical related  properties  
Han et al., (2008) observed that high surfactin micelle concentration affected the aggregation of 
amyloid ǃ-peptide (Aǃ (1-40)) into fibrils, a key pathological process associated with 
Alzheimer’s disease. Fengycin, another lipopeptide biosurfactant is also able to cause 
membrane perturbations (Deleu et al., 2008). Recent results by Eeman et al., (2009) emphasized 
the ability of fengycin to interact with the lipid constituents of the stratum corneum 
extracellular matrix and with cholesterol. Another interesting property of surfactin and its 
synthetic analogues is the ability to alter the nanoscale organisation of supported bilayers and 
to induce nanoripple structures with intriguing perspectives for biomedical and 
biotechnological applications (Bouffioux et al., 2007; Brasseur et al., 2007; Francius et al., 2008). 
Morita et al., (2010) investigated the cell activating property of MELs using cultured 
fibroblast and papilla cells, and a three dimensional cultured human skin model. The di-
acetylated MEL (MEL-A) produced from soybean oil significantly increased the viability of 
the fibroblast and of the papilla cells over 150% compared with that of control cells, 
suggesting potential use as new hair growth agent stimulating the papilla cells. Using a 
three-dimensional cultured human skin model, Morita et al., (2009b) observed that the 
viability of the SDS damaged cells was markedly improved by the addition of MEL-A in a 
dose-dependent manner. This demonstrated that MEL-A also had a ceramide-like 
moisturising activity toward the skin cells. Similarly, (Kitagawa et al., 2007, as cited in 
Worakitkanchanakul et al., 2008) reported that MEL-B shows excellent moisturizing 
properties, equivalent to those of natural ceramides, toward human skin.  
Trehalose lipids also display various interesting biological activities mainly due to their great 
tendency to partition into phospholipid membranes (Ortiz et al., 2008, 2009). In particular, the 
trehalose lipid was suggested to incorporate into the membrane bilayers and produce 
structural perturbations, which might affect the function of both phosphatidylethanolamine 
and phosphatidylserine membranes. Zaragoza et al., (2010) observed that a succinoyl trehalose 
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lipid produced by Rhodococcus sp. caused the swelling of human erythrocytes followed by 
hemolysis at concentrations well below its critical micellar concentration. They concluded that 
trehalose lipid caused the hemolysis of human erythrocytes by a colloid-osmotic mechanism, 
most likely by formation of enhanced permeability domains, or “pores” enriched with 
biosurfactant, within the erythrocyte membrane.  
Permealization of biological and artificial membranes was also reported to be induced by 
Pseudomonas aeruginosa dirhamnolipid (Sánchez et al., 2010).  In particular, it caused the 
hemolysis of human erythrocytes through a lytic mechanism, as shown by the similar rates 
of K+ and hemoglobin leakage, and by the absence of effect of osmotic protectants. Scanning 
electron microscopy showed that the addition of the biosurfactant changed the usual disc 
shape of erythrocytes into that of spheroechinocytes.    
4. Biotechnological and nanotechnological applications of surface-active 
compounds 
Biosurfactants, have been increasingly attracting attention in the field of nanotechnology 
(Kitamoto et al., 2005, 2009). During the last decade, unique properties of biosurfactants, like 
versatile self-assembling and biochemical properties, which are not usually observed in 
conventional chemical surfactants, have been reported (Kitamoto et al., 2005, 2009).  In 
recent years, the development of new functional structures and/or systems using self-
assembly of amphiphilic molecules has evolved into a dynamic and rapidly growing area of 
nanotechnology (Ariga et al., 2007, Shimizu et al., 2005, as cited in Kitamoto et al., 2009) due 
to their ability to self-assemble into hierarchically ordered structures using hydrogen 
bonding, hydrophobic and van der Waals interactions as mentiond earlier. 
Mannosylerythritol lipids (MELs) show the most interesting self-assembling properties and 
numerous related potential applications (Kitamoto et al., 2009). Konishi et al., (2007), Imura 
et al., (2007, 2008), and Ito et al., (2007), for example, developed and studied the kinetics of 
interactions in carbohydrate ligand systems composed of self-assembled monolayers of 
mannosylerythritol lipid-A (MEL-A) serving as a high-affinity, easy to handle and low-cost 
ligand system for immunoglobulin G and M and lectins..  
Table 1 below lists the latest discoveries in the biotechnological and nanotechnological fields 
applicable to biosurfactants, and in particular the latest successful results of 
mannosylerythritol lipids (MELs) application in the enhancement of the gene transfection 
efficiency of cationic liposomes as well as some interesting applications of glycolipids and 
other biosurfactants in drug delivery and gene therapy. Biosurfactants use as a “green” 
alternative for high-performance nanomaterials production and, in particular, for the 
synthesis and stabilization of metal-bound nanoparticles will also be described. 
 
Biosurfactant type Activity/application Study 
Mannosylerythritol 
lipids-A 
Ligand system for immunoglobulin G 
and M and lectins 
Konishi et al., (2007); 
Imura et al., (2007, 2008), 
Ito et al., (2007) 
 
DNA capsulation and membrane 
fusion with anionic liposomes 
Ueno et al., (2007a) 
 
In vitro promotion of gene transfection 
mediated by cationic liposomes   
Inoh et al., (2001, 2004, 
2010); Igarashi et al., 
(2006); Ueno et al., (2007b) 
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Biosurfactant type Activity/application Study 
 
In vivo promotion of liposome-
mediated gene transfection 
Inoh et al., (2009) 
 
Herpes simplex virus thymidine 
kinase gene therapy 
Maitani et al., (2006) 
 Water-in-oil microemulsions 
Worakitkanchanakul et al., 
(2008) 
 
Increase membrane fluidity of 
monolayers composed of L-ǂ-
dipalmitoylphosphatidylcholine 
(DPPC) 
Kitamoto et al., (2009) 
Mannosylerythritol 
lipids-B 
Self-assembling and vesicle-forming 
activity 




Deuterated rhamnolipids and 
sophorolipids 
Smyth et al., (2010b) 
 Cadmium sulfide nanoparticles Singh et al., (2011) 
 
Biocompatible microemulsions of 
lecithin/rhamnolipid/sophorolipid 
biosurfactants 
Nguyen et al., (2010) 
Rhamnolipids  
Silver nanoparticles with 
antibioticmicrobial activity 
Kumar et al., (2010) 
 
Nickel oxide nanoparticles by 
microemulsion technique 
Palanisamy & Raichur, 
(2009) 
 Silver nanoparticles  Xie et al., (2006) 
 ZnS nanoparticles Narayanan et al., (2010) 
 Microemulsions Xie et al., (2005, 2007) 
 Alcohol-free microemulsions Nguyen & Sabatini, (2009) 
Sophorolipids Cobalt nanoparticles Kasture et al., (2007) 
 Silver nanoparticles Kasture et al., (2008) 
 
Sophorolipid-coated silver and gold 
nanoparticles with antibacterial 
activity 
Singh et al., (2009, 2010)  
 
Biocompatible microemulsions of 
lecithin/rhamnolipid/sophorolipid 
biosurfactants 
Nguyen et al., (2010) 
Glycolipid 
biosurfactant 
Silver nanoparticles Kiran et al., (2010b) 
Fengycin and 
surfactin 
Enhancers for the skin accumulation 
of aciclovir 
Nicoli et al., (2010) 
Surfactin 
Surfactin-mediated synthesis of gold 
nanoparticles 
Reddy et al., (2009) 
 Cadmium sulfide nanoparticles Singh et al., (2011) 
Table 1. Examples of recent biosurfactant applications in the biotechnological and 
nanotechnological fields. 
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4.1 Liposomes and gene transfection 
Gene transfection into the cells is a fundamental technology not only for molecular and 
cellular biology processes but also a clinical gene therapy (Ueno et al., 2007b). Although 
several methods for gene transfection have been investigated (Felgner et al., 1989, Fujiwara, 
2000, Gao & Huang, 1991, Hatakeyama et al., 2007, Nishiyama et al., 2005, Ueno et al., 
2007b), more efficient and safe systems are still needed (Ueno et al., 2007b). Among the 
various methods, lipofection using cationic liposomes is considered to be a promising 
method for introducing foreign gene to the targeted cells due to their high transfection 
efficiency, low toxicity and immunogenicity, ease of preparation and targeted application 
(Farhood et al., 1992, Felgner et al., 1989, Kogure et al., 2007, Lasic, 1998, Nakanishi, 2003, 
Inoh et al., 2010). The physicochemical properties of cationic liposomes, such as lipid 
packing density, shape, and zeta-potential, have a significant effect on gene transfection 
efficiency (Lin et al., 2003, Takeuchi et al., 1996, Wittenberg et al., 2008, Xu et al., 1999, as 
cited by Inoh et al., 2010).  
Inoh et al., (2001) reported that MEL-A promoted DNA transfection efficiency mediated by 
cationic liposomes. Confocal laser scanning microscopic analysis showed the distribution of 
lipids and oligonucleotide DNA in MEL-A-containing liposome–DNA complex in the 
plasma membrane and the nucleus of target cells at 1 h after the addition of complex (Inoh 
et al., 2004). This suggests that MEL-A induces the membrane fusion between the target cells 
and the cationic liposomes, accelerating the efficiency of gene transfection significantly. 
Similarly, Igarashi et al., (2006) reported that MEL-A significantly increased the cellular 
association and the efficiency of gene transfection mediated by cationic liposomes in human 
cervix carcinoma Hela cells. Analysis of flow cytometric profiles clearly indicated that the 
amount of DNA associated with the cells was rapidly increased and sustained by addition 
of MEL-A to the liposome. Confocal microscopic observation also indicated that the MEL-
lipoplex distributed widely in the cytoplasm and DNA presence was intensely detected in 
cytoplasm around the nucleus.  
The above results suggested that MEL-A increased gene expression by enhancing the 
association of the lipoplexes with the cells in serum and, thus, MEL-liposome may prove a 
significant nonviral vector for gene transfection and gene therapy.  
In an attempt to explain how MEL-A-containing liposomes could accelerate gene 
transfection, Ueno et al., (2007a) examined MEL-containing liposomes properties such as 
their activity for DNA capsulation and membrane fusion abilities of cationic liposomes with 
artificial anionic liposomes. They observed that MEL-A-containing liposomes exhibited high 
activity in DNA incapsulation and membrane fusion with anionic liposomes, which are 
important properties for gene transfection. On the other hand, MEL-B- and MEL-C-
containing liposomes only increased either the incapsulation or the membrane fusion.  Ueno 
et al., (2007b) further examined the mechanism of the transfection mediated by cationic 
liposomes with NBD-conjugated MEL-A and reported that MEL-A distributed on the 
intracellular membranes through the plasma membranes of target cells, while the cationic 
liposomes with MEL-A fused to the plasma membranes within 20–35 min. Thereafter, they 
noted that the oligonucleotide released from the vesicles was immediately transferred to the 
nucleus. They therefore suggested that MEL-A was capable of promoting the transfection 
efficiency of target cells by inducing membrane fusion between liposomes and the plasma 
membrane of these cells. 
Recently Kitamoto et al., (2009) demonstrated that monolayers composed of L-ǂ-
dipalmitoylphosphatidylcholine (DPPC) containing MEL-A had greater membrane fluidity 
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than those containing only DPPC. It was also reported that unsaturated fatty acids in MEL-
A significantly influenced surface pressure and packing density in the monolayer and thus 
the physicochemical properties of MEL-A and MEL-A/lipids (Imura et al., 2008).  
Transfection efficiency of nano vectors with MEL-A was investigated in vivo on tumor cells 
in the mouse abdominal cavity (Inoh et al., 2009). When a complex of the nano vectors with 
MEL-A and plasmid DNA was injected intraperitoneally into C57BL/6J mice bearing 
B16/BL6 tumors, the biosurfactant significantly increased liposome-mediated gene 
transfection to the mouse tumor cells. The transfection efficiency of the plasmids into the 
solid tumors by the cationic liposomes of cholesteryl-3beta-carboxyamidoethylene-N-
hydroxyethylamine (OH-Chol) with MEL-A increased by approximatley 100-fold compared 
to that by the commercially available DC-Chol cationic liposomes without MEL-A. This 
suggests that nonviral vectors with MEL-A are very useful for gene transfection in vivo. The 
mechanisms of gene delivery by nano vectors with MEL-A and the numerous biological 
activities of these biosurfactants have been described by Nakanishi et al., (2009) and 
Kitamoto et al., (2009).   
Inoh et al., (2010) further investigated the effects of unsaturated fatty acid ratio within the 
MEL-A compound on the physicochemical properties and gene delivery into cells of cationic 
liposomes using MEL-A with three different unsaturated fatty acid (USF) component ratios. 
Gene transfer efficiency of cationic liposomes containing MEL-A (containing 21.5% USF) 
was much higher than that of those containing MEL-A (containing 9.1%USF) and MEL-A 
(containing 46.3%USF).  In particular, MEL-A (21.5% USF)-containing cationic liposomes 
induced highly efficient membrane fusion after addition of anionic liposomes and led to 
subsequent DNA release. 
Imaging analysis revealed that MEL-A (21.5% USF)-containing liposomes fused with  
the plasma membrane and delivered DNA into the nucleus of NIH-3T3 cells, MEL-A  
(46.3% USF)-containing liposomes fused with the plasma membrane did not deliver DNA 
into the nucleus, and MEL-A (9.1% USF)-containing liposomes neither fused with the 
plasma membrane nor delivered DNA into the nucleus. These results suggest that the  
MEL-A unsaturated fatty acid ratio significantly affects transfection efficiency due to 
changes in membrane fusion activity and the efficiency of DNA release from the liposomes.  
Mannosylerythritol lipid-B (MEL-B) with a different configuration of the erythritol moiety 
was found to self-assemble into a lamellar phase over remarkably wide concentration and 
temperature ranges; furthermore it showed great potential as a vesicle-forming lipid, 
suggesting its potential application in drug and gene delivery as well as in transdermal 
delivery systems (Worakitkanchanakul et al., 2008). In another work, a liposome vector 
containing betasitosterol beta-D-glucoside biosurfactant-complexed DNA was successfully 
used for herpes simplex virus thymidine kinase gene therapy (Maitani et al., 2006).  
4.2 Biosurfactants potential in drug delivery 
Properties such as detergency, emulsification, foaming and dispersion make biosurfactants 
interesting molecules with potential application in the field of drug delivery (Faivre & 
Rosilio, 2010). MEL-A for example has much higher emulsifying activity with soybean oil 
and tetradecane than polysorbate 80 (Kitamoto et al., 2009) and is able to form stable water-
in-oil microemulsions without addition of co-surfactant or salt (Worakitkanchanakul et al., 
2008).  
Rhamnolipids and sophorolipids have also been mixed with lecithins to prepare 
biocompatible microemulsions in which the phase behavior was unaffected by changes in 
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temperature and electrolyte concentration, making them desirable for cosmetic and drug 
delivery applications (Nguyen et al., 2010).  In 1988, rhamnolipid liposomes were patented 
as drug delivery systems, useful as microcapsules for drugs, proteins, nucleic acids, dyes 
and other compounds, as biomimetic models for biological membranes and as sensors for 
detecting pH variations. These novel liposomes were described as safe and biologically 
decomposable, with suitable affinity for biological organisms, stable and with long service 
and shelf life.  
The potential of lipopeptides, fengycin and surfactin to act as enhancers for the 
transdermal penetration and skin accumulation of aciclovir was also recently investigated 
(Nicoli et al., 2010) to elucidate any possible synergistic effect between surfactin and 
fengycin associated with anodal iontophoresis. It was demonstrated that these 
lipopeptides did not enhance aciclovir transport across the skin (not even when associated 
with iontophoresis) although they increased aciclovir concentration in the epidermis by a 
factor of 2 (Nicoli et al., 2010). 
Microemulsion produced using biosurfactant are thermodynamically stable and their 
isotropic systems that form spontaneously-consisting of microdomains of oil or water 
stabilized by an interfacial film - in addition to their long-term stability, easy preparation 
and high solubilization capacity are considered to be very promising liquid vehicles for 
future drug delivery systems (Date et al., 2008, as cited in Faivre & Rosilio, 2010). 
4.3 Nanoparticles 
Another interesting application for natural surfactant is the the synthesis of metal-bound 
nanoparticles as an alternative environmentally friendly technology (Sharma et al., 2009). 
Nanomaterials synthesis and use has been an active research area due to interesting 
properties of the nanomaterials as compared to bulk material use (Palanisamy & Raichur, 
2009). Metal nanoparticles have beening explored in various fields such as catalysis, 
mechano- and electrical applications and biomedical uses (Van Bogaert & Soetaert, 2010).  
The reduction in size gives rise to size dependent effects such as high surface to volume 
ratio, lower melting point, changes in electronic structure and changes in lattice structure 
and interatomic distances which in turn affect the processing parameters (Liveri, 2006, as 
cited in Palanisamy & Raichur, 2009).  
The use of gold nanoparticles, in particular, is currently undergoing a dramatic expansion in 
the field of drug and gene delivery, targeted therapy and imaging technologies (Boisselier & 
Astruc, 2009; Pissuwan et al., 2009, 2011). Potential therapeutic applications of gold 
compound and gold nanoparticles also include anti-HIV activity, anti-angiogenesis, anti-
malarial activity, anti-arthritic activity and biohydrogen production (Kalishwaralal et al., 
2010).  Silver nanoparticles are also been reported to possess anti-fungal activity, anti-
inflammatory effect, anti-viral, anti-angiogenesis and anti-platelet activity (Kalishwaralal et 
al., 2010). 
Reddy et al., (2009) successfully synthesized surfactin-mediated gold nanoparticles and 
investigated the effects of proton concentrations and temperature on the morphology of the 
obtained nanoparticles. It was demonstrated that the nanoparticles synthesized at pH 7 and 
9 remained stable for 2 months, while aggregates were observed at pH 5 within 24 h.  
Moreover, the nanoparticles formed at pH 7 were uniform in shape and size and were 
polydispersed and anisotropic at pH 5 and 9. The nanoparticles synthesized produced at 
room temperature were monodispersed and were more uniform when compared to those 
formed at 4°C.  More recently they also carried out a biological synthesis of gold and silver 
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nanoparticles using the bacteria Bacillus subtilis. Gold nanoparticles were synthesized both 
intra- and extracellularly, while silver nanoparticles were exclusively formed extracellularly 
(Reddy et al., 2010). According to the Authors the nanoparticles were stabilized by the 
surface-active molecules i.e., surfactin or other biomolecules released into the solution by B. 
subtilis.  
Surfactin produced by Bacillus amyloliquefaciens KSU-109 was also used for the synthesis of 
cadmium sulfide nanoparticles which remained stable up to six months without 
compromising their functionality (Singh et al., 2011). This kind of nanoparticles works as 
semiconductors with unique optical properties and tunable photo-luminescence allowing 
potential applications in solar energy conversion, nonlinear optical, photoelectrochemical cells 
and heterogeneous photocatalysis (Singh et al., 2011).  In addition, surfactin produced by 
strain KSU-109 was easily extracted and used without further purification for nanoparticles 
stabilization under ambient conditions (Singh et al., 2011). Such simple, inexpensive and 
environmental friendly procedure of obtaining surfactin offers a further advantage of use in 
nanobiotechnology for the large-scale production of highly stable metal nanoparticles. 
Both rhamnolipids and sophorolipids have also been successfully used for the synthesis and 
stabilization of metal-bound nanoparticles. Purified rhamnolipids from P. aeruginosa strain 
BS-161R were used to synthesize silver nanoparticles which exhibited good antibiotic 
activity against both Gram-positive and Gram-negative pathogens and Candida albicans, 
suggesting their broad spectrum antimicrobial activity (Kumar et al., 2010).  In another 
work, a glycolipid biosurfactant produced from sponge-associated marine bacteria 
Brevibacterium casei MSA19, using agro-industrial and industrial waste as substrate, were 
used as a “green” stabilizer for the synthesis of stable and uniform silver nanoparticles 
(Kiran et al., 2010b). The biosurfactant acted as stabilization agent and prevented the 
formation of aggregates. 
Palanisamy & Raichur, (2009) also described a simple and eco-friendly method for 
synthesizing spherical nickel oxide nanoparticles by microemulsion technique using 
rhamnolipids as alternative surfactant. The synthesized nanoparticles were found to be fully 
crystalline and spherical in shape with uniform distribution and increasing the pH of the 
solution decreased the size of the nanoparticles. Xie et al., (2006) were also able to synthesize 
silver nanoparticles in rhamnolipid reverse micelles while in another study rhamnolipids 
were used as capping agents for the synthesis of ZnS nanoparticles in aqueous medium 
(Narayanan et al., 2010).  
Sophorolipids were also tested for use in nanoparticles synthesis and reported to be good 
reducing and capping agents for cobalt and silver particles (Kasture et al., 2007, 2008, as 
cited in Van Bogaert & Soetaert, 2010). Singh et al., (2009) demonstrated the antibacterial 
activity of sophorolipid-coated silver and gold nanoparticles against both Gram-positive 
and –negative bacteria. They also verified that sophorolipid-coated gold nanoparticles were 
more cyto and geno-compatible with respect to silver nanoparticles (Singh et al., 2010).  
They also plan to investigate these nanoparticles suitability for medical and diagnostic 
applications.  
Recently, methodologies for the biological synthesis of metal nanoparticles using microbes 
have also been described (Narayanan & Sakthivel, 2010; Kalishwaralal et al., 2010; Reddy et 
al., 2010). In addition Smyth et al., (2010b) reported on the production of selectively 
deuterated rhamnolipids and sophorolipids using deuterated substrates. The production of 
such deuterated biosurfactants, in particular, or other bioactive microbial products in 
general, in which distinct pattern of labeling could be achieved resulting in varing molecular 
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weight products and or stereochemistry unrecognised by existing degradative enzymes is 
very improtant. Such molecules would have great future implications with regards to 
efficacy and/or persistence or the development of resistance for some bioactives particularly 
in biomedical related applications.  
4.4 Microemulsions 
Microemulsions are thermodynamically stable, isotropic dispersions of oil, water and 
surfactant (Rosen, 1989, as cited in Nguyen et al., 2010). Microemulsion systems produce 
high solubilization capacity and ultralow interfacial tensions of oil and water, making them 
desirable in practical applications such as enhanced oil recovery, drug delivery, food and 
cosmetic applications (Bourrel & Schechter, 1988, Kogan & Garti, 2006, Komesvarakul et al., 
2006, Lawrence & Rees. 2000, Vandamme, 2002, Yuan et al., 2008, as cited in Nguyen et al., 
2010). Xie et al., 2005 demonstrated that rhamnolipids could be successfully used to form 
microemulsions using medium chain alcohols as cosurfactant. Subsequently, the same 
Authors observed that the phase behavior and microstructure of these microemulsions were 
rational to the conformational changes of rhamnolipid molecules at the interface of 
oil/water (Xie et al., 2007). Microemulsion technique using oil–water–surfactant mixture has 
also emerged as a promising method for nanoparticle synthesis and can be used to 
synthesize different types of particles (Eastoe et al., 2006, as cited in Palanisamy & Raichur, 
2009). Palanisamy & Raichur, (2009), for example, successfully used rhamnolipids as the 
surfactant to synthesize spherical nickel oxide nanoparticles by microemulsion technique. In 
another work, Nguyen & Sabatini, (2009) were able to formulate alcohol-free 
microemulsions using rhamnolipid biosurfactant and rhamnolipid mixtures. 
Lecithin-based microemulsions have proven to be desirable in biocompatible formulations 
due to their tendency to mimic the phospholipid nature of cell membranes (Nguyen et al., 
2010). In a recent report Nguyen et al., (2010) formulated and evaluated microemulsions of 
lecithin/rhamnolipid/sophorolipid biosurfactants with a range of oils.  Sophorolipid played 
an important role as the hydrophobic component in these formulations and the phase 
behavior of these biocompatible microemulsions did not change significantly with changing 
temperature and electrolyte concentration, making them desirable for cosmetic and drug 
delivery applications.  
4.5 A survey over biotechnological commercial applications and patents of 
biosurfactants and bioemulsifiers 
Due to their broad-range of functional properties and the diverse synthetic capabilities of 
microbes, biological surfactants and emulsifiers have been recently used in various 
industries like detergents and soaps, petroleum, textile, agriculture, cosmetic, medicine and 
food (Banat et al., 2000, 2010).  Due to their environmental acceptability, biodegradability 
and lower toxicity, they are generally accepted as good candidates to substitute synthetic 
surfactants. Commercial applications of biosurfactants and bioemulsifiers in the 
biotechnological field are mainly related to the oil industry, enhanced oil recovery and 
bioremediation technologies (Desai & Banat, 1997).  However, interesting marketable 
products and patents have been issued in the last few years in the health care and cosmetic 
industries, reviewed by Shete et al., (2006) and Banat et al., (2010).  
Sugar-based biosurfactants, sophorolipids in particular, are very attractive in these fields, 
because of their good detergency, emulsifying, foaming and dispersing properties (Faivre & 
Rosilio, 2010). Sophorolipids are better solubilizers than emulsifiers, but their derivatives 
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containing propylene glycol have excellent hygroscopic properties and are applied as 
moisturizer or softener in cosmetic products (Faivre & Rosilio, 2010). For example, a product 
containing 1 mol of sophorolipid and 12 mol of propylene glycol has excellent skin 
compatibility and is used commercially as a skin moisturizer (Yamane, 1987, as cited in 
Desai & Banat 1997). Sophorolipid is commercially used by Kao Co. Ltd. as a humectant for 
cosmetic makeup brands such as Sofina. This company has developed a fermentation 
process for sophorolipid production, and after a two-step esterification process, the product 
finds application in lipstick and as moisturizer for skin and hair products (Inoue et al., 1979 
a, 1979b, as cited in Desai & Banat, 1997). Moreover, sophorolipids are also believed to 
stimulate the leptin synthesis through adipocytes, in this way reducing the subcutaneous fat 
overload (Pellecier & André, 2004, as cited in Van Bogaert & Soetaert, 2010). 
The French company Soliance (http://www.groupesoliance.com) produces sophorolipid-
based cosmetics for the body and skin and the Korean MG Intobio Co. commercializes 
Sopholine cosmetics (Van Bogaert & Soetaert, 2010). They are also found in cleaning soap 
mixtures (EcoverTM products). Despite the high number of scientific publications and 
patents, industrial surfactin applications still remain quite limited (Jacques, 2010). Sold by 
SIGMA and SHOWA DENKO for analytical or laboratory purposes, the compound is also 
available in several Japanese cosmetic products.   
During the last decades, many patents have been issued worldwide in relation with 
applications of biosurfactants and bioemulsifiers in the health care field (Shete et al., 2006). 
Bioemulsifiers produced by Acinetobacter calcoaceticus, for examples, have been used in 
shampoos and soaps against acne and eczema and in personal care products. The skin 
cleansing cream and lotion containing these bioemulsifiers have, among other properties, 
the ability to interfere with microbial adhesion on skin or hair (Hayes et al., 1989, 1990, 1991, 
1992, as cited in Shete et al., 2006). Viscosin and analogues have been patented as 
antibacterial, antiviral, antitrypanosomal therapeutic compounds that inhibit the growth of 
Mycobacterium tuberculosis, Herpes simplex virus 2 and/or Trypanosoma cruzi (Burke et al., 
1999, as cited in Shete et al., 2006). Lactobacillus biosurfactants have also been patented as 
inhibitors of adherence and colonization of bacterial pathogens on medical devices (Reid et 
al., 2000).  
Another interesting patented area is related to antimicrobial biosurfactant peptides 
produced by probiotic strains able to selectively bind to collagen and inhibit infections 
around wounds at the site of implants and biofilms associated with infections in mammals 
(Howard et al., 2002, as cited in Shete et al., 2006). Sophorolipids, in particular have been the 
object of many patents as moisturizing agents and for the amelioration of skin physiology, 
skin restructuration and repair (Shete et al., 2006). Sophorolipids are also used for the 
treatment of skin, as an activator of macrophages, and as agent in fibrinolytic healing, 
desquamating and depigmenting process (Maingault, 1999 as cited in Shete et al., 2006). A 
germicidal composition containing fruit acids, a surfactant and a sophorolipid biosurfactant, 
able to kill in 30 seconds 100% of E. coli, Salmonella and Shigella, has been patented for 
cleaning fruits, vegetable, skin and hair (Pierce & Heilman, 2001).   
Rhamnolipids in comparison have been patented in a process to make some liposomes and 
emulsions (Ishigami & Suzuki 1997; Ramisse et al., 2000) both important in the cosmetic 
industry. More recently an activator and anti-aging agent containing MEL as active 
ingredient has been patented (Suzuki et al., 2010). Another recent invention is directed to 
polymeric acylated biosurfactants that can self-assemble or auto-aggregate into polymeric 
micellar structures useful in topically-applied dermatologic products (Owen & Fan, 2010). 
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Another patent has been deposited about a biosurfactant composition produced by a new B. 
licheniformis strain, with anti-adhesion activity against biofilm producer microbial pathogens 
(Martinotti et al., 2009).   
5. Conclusions and perspectives 
As evidenced by the growing number of publications on the topic of biosurfactants, there is 
an increasing interest in the study of these molecules and their potential applications. The 
demand for new specialty surfactants in the agriculture, cosmetic, food, pharmaceutical, and 
environmental industries is steadily increasing and biosurfactants, as effective and 
environmentally compatible compounds, perfectly meet this demand (Banat et al., 2000, 
2010;  Mukherjee et al., 2006).  
The most important limitation for the commercial use of biosurfactants is the complexity 
and high cost of production, which has limited the development of their use on a large scale 
(Soberón-Chávez & Maier, 2010). However, the proven antimicrobial, anti-adhesive, 
immune-modulating properties of biosurfactants and the recent successful applications in 
gene therapy, immunotherapy and medical insertion safety suggest that it is worth 
persisting in this field. Moreover, in pharmaceutical and biomedical sectors, the high cost of 
production could be compensated for by the small amounts of product required. In fact, it 
has been elucidated that biosurfactants used as pharmaceutical agents are needed only in 
very low concentrations (Cameotra & Makkar, 2004). Prerequisites for making biosurfactant 
production more profitable and economically feasible include optimized 
growth/production conditions and novel and efficient multi-step downstream processing 
methods as well as the use of recombinant varieties of microorganisms or selected 
hyperproducing mutants, which can grow on a wide range of cheap renewable substrates 
(Muthusamy et al., 2008). 
Recent advances in the area of biomedical application are probably going to take the lead 
due to higher potential economic returns. Moreover, due to their self-assembly properties, 
new and fascinating applications in nanotechnology are predicted for biosurfactants 
(Kitamoto et al., 2009; Palanisamy, 2008; Reddy et al., 2009).  In-depth studies of their 
natural roles in microbial competitive interactions, cell-to-cell communication, pathogenesis, 
motility and biofilm formation and maintenance could suggest improved and interesting 
future applications. 
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